Chloroprene

CASRN 126-99-8

Health Hazard Assessments for Effects Other than Cancer


Reference Dose for Oral Exposure (RfD) (PDF) (30 pp, 307 K) last updated: 09/30/2010
Information reviewed but value not estimated.

Reference Concentration for Inhalation Exposure (RfC) (PDF) (30 pp, 307 K) last updated: 09/30/2010

RfC (mg/m3) System Basis PoD Composite UF Confidence
2 x10-2 Nervous, Immune, Respiratory Increase in incidence of olfactory atrophy, alveolar hyperplasia, and splenic hematopoietic proliferation in male F344/N rats, female F344/N rats, and female B6C3F1 mice, respectively BMDL (HEC): 2
mg/m3
100 Medium/High

Cancer Assessment


Weight of Evidence for Cancer (PDF) (30 pp, 307 K) last updated: 09/30/2010

WOE Characterization Framework for WOE Characterization
Likely to be carcinogenic to humans Guidelines for Carcinogen Risk Assessment (US EPA, 2005)
Basis:
  • Under the Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005), there is evidence that chloroprene is "likely to be carcinogenic to humans"
  • This may be a synopsis of the full weight-of-evidence narrative.

Quantitative Estimate of Carcinogenic Risk from Oral Exposure (PDF) (30 pp, 307 K)

Information reviewed but value not estimated.

Quantitative Estimate of Carcinogenic Risk from Inhalation Exposure (PDF) (30 pp, 307 K)

Inhalation Unit Risk: 3 x10 -4 per µg/m3
Extrapolation Method: Multistage model with linear extrapolation from the point of departure (BMDL), summed risk.
Tumor site(s): Reproductive, Ocular, Other, Hepatic, Gastrointestinal, Respiratory, Dermal
Tumor type(s): alveolar/ bronchiolar adenoma or carcinoma hemangioma/ hemangiosarcoma (all organs) mammary gland adenocarcinoma, carcinoma, or adenoacanthoma forestomach squamous cell papilloma or carcinoma hepatocellular adenoma or carcinoma Harderian gland adenoma or carcinoma skin sarcoma and Zymbal's gland carcinoma (NTP, 1998)


You will need Adobe Reader to view some of the files on this page. See EPA’s PDF page to learn more.